Stay updated on Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page.

Latest updates to the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include the term 'Metastatic Breast Cancer' and a new EudraCT number, while significant details regarding the study's design, inclusion and exclusion criteria have been removed.SummaryDifference14%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 17, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version release, moving from v2.14.2 to v2.14.3, and the last update date has changed from February 17, 2025, to March 25, 2025.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has been updated to reflect a new study on Trastuzumab Emtansine in combination with Atezolizumab, with significant changes in the number of study locations and the estimated last update date. The study now includes 50 locations compared to the previous 108, and the last update is now estimated for February 2025.SummaryDifference29%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1.0%
Stay in the know with updates to Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page.